Last 32 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.13 | — | — | — | — | — | — | — | — | 1.78 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | 1.23 | — | 119.87 | 90.41 | 57.93 | 144.24 | 138.37 | 79.01 | 26.62 | 92.71 | 35.48 | 52.31 |
| — | — | — | — | — | — | — | — | — | -97.9% | — | -13.4% | +14.4% | +117.7% | +55.6% | +290.0% | +51.0% | +36.4% | +378.5% | +86.0% | +78.9% | |
| P/B Ratio | 0.67 | 0.90 | 1.75 | 2.05 | 2.90 | 2.01 | 0.79 | 1.04 | 0.87 | 1.44 | 2.74 | 1.78 | 1.07 | 0.74 | 0.57 | 1.91 | 1.69 | 1.25 | 5.08 | 3.39 | 4.48 |
| — | -55.2% | +122.7% | +96.8% | +235.3% | +39.4% | -71.3% | -41.2% | -19.4% | +94.5% | +376.8% | -6.8% | -36.4% | -40.6% | -88.7% | -43.8% | -62.3% | -59.6% | +74.9% | +0.2% | +117.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | 1.67 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 1.50 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | 1.43 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | 78.4% | — | 41.7% | -2302.9% | -1928.3% | -5566.1% | -2610.4% | -1198.9% | -1229.4% | -587.9% | -273.9% | -246.0% |
| — | — | — | — | — | — | — | — | — | +104.1% | — | +101.6% | -92.1% | -56.9% | -846.7% | -853.0% | -387.3% | -314.4% | -143.9% | +2.9% | +67.0% | |
| Operating Margin | — | — | — | — | — | — | — | — | — | 65.6% | — | -3213.8% | -3615.3% | -3101.4% | -9471.2% | -4083.6% | -2058.7% | -1819.1% | -1003.0% | -465.8% | -420.9% |
| — | — | — | — | — | — | — | — | — | +102.1% | — | +21.3% | -75.6% | -70.5% | -844.3% | -776.7% | -389.2% | -304.9% | -181.8% | -10.6% | +59.3% | |
| Net Margin | — | — | — | — | — | — | — | — | — | 69.3% | — | -2842.3% | -3164.3% | -2702.6% | -8399.7% | -3815.3% | -2006.6% | -1810.3% | -1000.3% | -464.3% | -419.8% |
| — | — | — | — | — | — | — | — | — | +102.6% | — | +25.5% | -57.7% | -49.3% | -739.7% | -721.7% | -378.0% | -303.7% | -181.8% | -10.7% | +59.1% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -25.3% | -8.1% | -5.5% | -7.4% | -9.5% | -7.8% | -7.5% | -6.6% | -8.2% | 22.7% | -12.0% | -10.1% | -9.0% | -8.3% | -10.0% | -12.4% | -12.4% | -19.5% | -12.9% | -10.6% | -12.1% |
| — | -4.1% | +26.1% | -12.2% | -16.2% | -134.4% | +37.5% | +34.4% | +9.7% | +373.3% | -19.7% | +18.8% | +27.2% | +57.3% | +22.7% | -17.1% | -2.4% | -18.3% | +15.1% | +40.0% | +27.3% | |
| ROA | -23.9% | -7.8% | -5.3% | -7.0% | -8.8% | -7.3% | -7.0% | -6.1% | -7.6% | 21.0% | -11.0% | -9.2% | -8.3% | -7.7% | -9.0% | -11.0% | -10.7% | -16.4% | -11.4% | -9.6% | -10.5% |
| — | -6.4% | +24.5% | -14.0% | -16.7% | -134.9% | +36.0% | +33.5% | +8.7% | +374.8% | -21.2% | +16.2% | +22.6% | +53.3% | +20.6% | -15.1% | -1.8% | -22.8% | +4.2% | +26.6% | +20.3% | |
| ROIC | -36.2% | -5.4% | -7.4% | -10.8% | -9.7% | -8.0% | -7.9% | -7.5% | -9.7% | 20.7% | -11.1% | -9.2% | -8.4% | -7.8% | -9.3% | -13.0% | -13.1% | -16.8% | -11.2% | -10.4% | -14.2% |
| — | +32.5% | +5.6% | -43.0% | -0.6% | -138.4% | +28.7% | +18.0% | -15.0% | +366.9% | -19.3% | +29.6% | +35.7% | +53.7% | +17.4% | -25.9% | +8.1% | +53.9% | +71.4% | +77.5% | +67.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.07 | 0.06 | 0.09 | 0.08 | — | — |
| — | -51.9% | -50.4% | -48.0% | -0.6% | +0.2% | -25.3% | -22.8% | -21.0% | -20.1% | +9.8% | -31.8% | -29.0% | -51.5% | -46.3% | — | — | — | +259554.8% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.18 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 27.40 | 31.35 | 34.33 | 27.40 | 17.70 | 24.42 | 28.71 | 22.63 | 18.44 | 22.07 | 20.38 | 17.71 | 18.65 | 19.11 | 21.02 | 12.41 | 15.49 | 7.88 | 10.94 | 11.77 | 11.95 |
| — | +28.4% | +19.6% | +21.1% | -4.0% | +10.6% | +40.9% | +27.8% | -1.1% | +15.5% | -3.0% | +42.7% | +20.4% | +142.6% | +92.1% | +5.4% | +29.6% | +38.0% | +68.4% | +178.6% | +139.3% | |
| Quick Ratio | 27.40 | 31.35 | 34.33 | 27.40 | 17.70 | 24.42 | 28.71 | 22.63 | 18.44 | 22.07 | 20.38 | 17.71 | 18.65 | 19.11 | 21.02 | 12.46 | 15.49 | 7.88 | 10.94 | 11.77 | 11.75 |
| — | +28.4% | +19.6% | +21.1% | -4.0% | +10.6% | +40.9% | +27.8% | -1.1% | +15.5% | -3.0% | +42.2% | +20.4% | +142.6% | +92.1% | +5.8% | +31.9% | +40.3% | +71.0% | +171.9% | +143.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 32 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FULC stock.
Fulcrum Therapeutics, Inc.'s current P/E is -3.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Fulcrum Therapeutics, Inc.'s business trajectory between earnings reports.